Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning

被引:39
|
作者
Morofuji, Yoichi [1 ]
Nakagawa, Shinsuke [2 ]
机构
[1] Nagasaki Univ, Dept Neurosurg, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan
[2] Nagasaki Univ, Dept Med Pharmacol, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan
关键词
Blood-brain barrier; central nervous system disease; drug development; drug repositioning; neurotherapeutics; penetration efficacy; MICROVASCULAR ENDOTHELIAL-CELLS; MEMBRANE-PERMEABILITY ASSAY; EXPERIMENTAL CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; ENDOVASCULAR TREATMENT; ELECTRICAL-RESISTANCE; VASCULAR PROTECTION; PARKINSONS-DISEASE; NEUROVASCULAR UNIT; REPURPOSED DRUGS;
D O I
10.2174/1381612826666200224112534
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An important goal of biomedical research is to translate basic research findings into practical clinical implementation. Despite the advances in the technology used in drug discovery, the development of drugs for central nervous system diseases remains challenging. The failure rate for new drugs targeting important central nervous system diseases is high compared to most other areas of drug discovery. The main reason for the failure is the poor penetration efficacy across the blood-brain barrier. The blood-brain barrier represents the bottleneck in central nervous system drug development and is the most important factor limiting the future growth of neurotherapeutics. Meanwhile, drug repositioning has been becoming increasingly popular and it seems a promising field in central nervous system drug development. In vitro blood-brain barrier models with high predictability are expected for drug development and drug repositioning. In this review, the recent progress of in vitro BBB models and the drug repositioning for central nervous system diseases will be discussed.
引用
收藏
页码:1466 / 1485
页数:20
相关论文
共 50 条
  • [41] MicroRNAs in central nervous system diseases: A prospective role in regulating blood-brain barrier integrity
    Ma, Feifei
    Zhang, Xuejing
    Yin, Ke-Jie
    EXPERIMENTAL NEUROLOGY, 2020, 323
  • [42] The Blood-Brain Barrier and Drug Delivery
    Olbricht, William
    CHEMICAL ENGINEERING PROGRESS, 2013, 109 (03) : 31 - 34
  • [43] Current State and Future Perspectives in QSAR Models to Predict Blood-Brain Barrier Penetration in Central Nervous System Drug R&D
    Morales, Juan F.
    Scioli Montoto, Sebastian
    Fagiolino, Pietro
    Ruiz, Maria E.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2017, 17 (03) : 247 - 257
  • [44] In vitro models for the blood-brain barrier
    Garberg, P
    Ball, M
    Borg, N
    Cecchelli, R
    Fenart, L
    Hurst, RD
    Lindmark, T
    Mabondzo, A
    Nilsson, JE
    Raub, TJ
    Stanimirovic, D
    Terasaki, T
    Öberg, JO
    Österberg, T
    TOXICOLOGY IN VITRO, 2005, 19 (03) : 299 - 334
  • [45] The blood-brain barrier and drug transport to the brain
    de Boer, AG
    Gaillard, PJ
    STP PHARMA SCIENCES, 2002, 12 (04): : 229 - 234
  • [46] The blood-brain barrier and brain drug delivery
    Koziara, J. M.
    Lockman, P. R.
    Allen, D. D.
    Mumper, R. J.
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2006, 6 (9-10) : 2712 - 2735
  • [47] In vitro models of the blood-brain barrier
    Garberg, P
    ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 1998, 26 (06): : 821 - 847
  • [48] Caveolae-mediated transport at the injured blood-brain barrier as an underexplored pathway for central nervous system drug delivery
    Sorets, Alexander G.
    Rosch, Jonah C.
    Duvall, Craig L.
    Lippmann, Ethan S.
    CURRENT OPINION IN CHEMICAL ENGINEERING, 2020, 30 (30) : 86 - 95
  • [49] In vitro models of the blood-brain barrier
    Wilhelm, Imola
    Fazakas, Csilla
    Krizbai, Istvan A.
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2011, 71 (01) : 113 - 128
  • [50] Drug repositioning for new CNS injury treatment: Targeting on protection of blood-brain barrier
    Suzuki, Y.
    Kadoya, K.
    Endo, T.
    Matsui, Y.
    Rufei, Y.
    Asano, T.
    Nakagawa, S.
    Iwasaki, N.
    GLIA, 2019, 67 : E637 - E638